• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

BUCINDOLOL Drug Record

  • Summary
  • Interactions
  • Claims
  • BUCINDOLOL chembl:CHEMBL321582

    Alternate Names:

    BUCINDOLOL

    Drug Info:

    FDA Approval not approved
    Drug Class Small molecule
    Drug Indications for treatment of heart failure
    (0 More Sources)

    Publications:

    Rau T et al., 2012, Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients., Clin Pharmacol Ther
    Huntgeburth M et al., 2011, The Arg389Gly β1-adrenoceptor gene polymorphism influences the acute effects of β-adrenoceptor blockade on contractility in the human heart., Clin Res Cardiol
    Baudhuin LM et al., 2010, Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure., Am J Cardiol
    Metra M et al., 2010, Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure., Cardiovasc Drugs Ther
    Filigheddu F et al., 2010, Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension., Pharmacogenomics
    Chen L et al., 2007, Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol., Pharmacogenet Genomics
    Lobmeyer MT et al., 2007, Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure., Pharmacogenet Genomics
    Liu J et al., 2006, beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension., Clin Pharmacol Ther
    Terra SG et al., 2005, Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy., Pharmacogenet Genomics
    de Groote P et al., 2005, Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure., Pharmacogenet Genomics
    Terra SG et al., 2005, beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure., Clin Pharmacol Ther
    Liu et al., 2003, Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol., Clin. Pharmacol. Ther.
    Mialet Perez J et al., 2003, Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure., Nat Med
    White HL et al., 2003, An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study., Eur J Heart Fail
    Johnson et al., 2003, Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol., Clin. Pharmacol. Ther.
    Sofowora GG et al., 2003, A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade., Clin Pharmacol Ther
    O'Connor CM et al., 2012, Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms., PLoS One
  • BUCINDOLOL   ADRB1

    Interaction Score: 4.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name bucindolol hydrochloride,Gencaro
    Novel drug target Established target

    PMIDs:
    22617224 21311897 20643254 20352314 20235788 18075464 17496726 16815314 15864115 15861037 15735607 14534524 14502278 12921807 12844134 12709726


    Sources:
    TdgClinicalTrial PharmGKB TTD

  • BUCINDOLOL   ADRA2C

    Interaction Score: 0.66

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23071495


    Sources:
    PharmGKB

  • BUCINDOLOL   ADRB2

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name bucindolol hydrochloride,Gencaro
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TTD

  • TdgClinicalTrial: BUCINDOLOL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications for treatment of heart failure
    Drug Class Small molecule
    FDA Approval not approved

    Publications:

  • PharmGKB: bucindolol

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    O'Connor CM et al., 2012, Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms., PLoS One
    Terra SG et al., 2005, Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy., Pharmacogenet Genomics
    Baudhuin LM et al., 2010, Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure., Am J Cardiol

  • TTD: BUCINDOLOL

    • Version: 2020.06.01

    Alternate Names:
    D03MZJ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL321582

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21